Cargando…

The Clinical Features of Graves' Orbitopathy with Elevated Intraocular Pressure

BACKGROUND: To investigate the clinical characteristics of Graves' orbitopathy (GO) with elevated intraocular pressure (IOP) using the European Group of Graves' Orbitopathy (EUGOGO) system. METHODS: In this retrospective study, the clinical data of GO patients with elevated IOP (≥21 mmHg)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fan, Shu-Xian, Zeng, Peng, Li, Zi-Jing, Wang, Jing, Liang, Jia-Qi, Liao, Yun-Ru, Hu, Yu-Xin, Xu, Ming-Tong, Wang, Mei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7850838/ https://www.ncbi.nlm.nih.gov/pubmed/33564472 http://dx.doi.org/10.1155/2021/9879503

Ejemplares similares

Topical Treatment of Elevated Intraocular Pressure in Patients with Graves’ Orbitopathy
por: Gumińska, Magdalena, et al.
Publicado: (2020)

Evaluation of the Graves' Orbitopathy-Specific Quality of Life Questionnaire in the Mainland Chinese Population
por: Zeng, Peng, et al.
Publicado: (2019)

Graves' Orbitopathy
por: Hiromatsu, Yuji, et al.
Publicado: (2015)

Immunological Features of Paranasal Sinus Mucosa in Patients with Graves’ Orbitopathy
por: Lu, Yi, et al.
Publicado: (2021)

Asymmetric Graves’ Orbitopathy
por: Panagiotou, Grigorios, et al.
Publicado: (2020)

The Role of the Microbiota in Graves’ Disease and Graves’ Orbitopathy
por: Hou, Jueyu, et al.
Publicado: (2021)

Antioxidant Therapy in Graves’ Orbitopathy
por: Lanzolla, Giulia, et al.
Publicado: (2020)

Current Knowledge on Graves’ Orbitopathy
por: Gontarz-Nowak, Katarzyna, et al.
Publicado: (2020)

Orbital Signaling in Graves’ Orbitopathy
por: Draman, Mohd Shazli, et al.
Publicado: (2021)

Distinctive Features of Orbital Adipose Tissue (OAT) in Graves’ Orbitopathy
por: Zhang, Lei, et al.
Publicado: (2020)

Graves’ disease and Graves’ orbitopathy following COVID-19
por: Lanzolla, G., et al.
Publicado: (2021)

Anti-nuclear autoantibodies in Graves’ disease and Graves’ orbitopathy
por: Lanzolla, G., et al.
Publicado: (2022)

Mechanisms That Underly T Cell Immunity in Graves’ Orbitopathy
por: Fang, Sijie, et al.
Publicado: (2021)

Graves′ orbitopathy: Management of difficult cases
por: Wiersinga, Wilmar M.
Publicado: (2012)

Endoscopic orbital decompression for Graves’ orbitopathy
por: Lal, Priti, et al.
Publicado: (2013)

Thyrotropin receptor antibodies and Graves’ orbitopathy
por: Diana, T., et al.
Publicado: (2020)

Current concepts regarding Graves’ orbitopathy
por: Bartalena, Luigi, et al.
Publicado: (2022)

Update on the surgical management of Graves’ orbitopathy
por: Baeg, Joonyoung, et al.
Publicado: (2023)

Significance of HLA in the development of Graves’ orbitopathy
por: Stasiak, Magdalena, et al.
Publicado: (2023)

Establishment and Comparison of Two Different Animal Models of Graves’ Orbitopathy
por: Wang, Wei, et al.
Publicado: (2023)

Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement
por: Perros, P., et al.
Publicado: (2017)

Planning health care for patients with Graves’ orbitopathy
por: Sasim, Inna V., et al.
Publicado: (2008)

Surgical complications in orbital decompression for Graves' orbitopathy
por: Sellari-Franceschini, S., et al.
Publicado: (2016)

Serum thyroglobulin is associated with orbitopathy in Graves’ disease
por: Khamisi, S., et al.
Publicado: (2021)

Correction to: Thyrotropin receptor antibodies and Graves’ orbitopathy
por: Diana, T., et al.
Publicado: (2021)

Roles of four targets in the pathogenesis of graves' orbitopathy
por: Ren, Ziqiang, et al.
Publicado: (2023)

Atypical Asymmetric Presentation of Severe Graves’ Orbitopathy
por: Gupta, Priyanka, et al.
Publicado: (2023)

Elevated percentage of HLA-DR(+) and ICAM-1(+) conjunctival epithelial cells in active Graves’ orbitopathy
por: Pawlowski, P., et al.
Publicado: (2014)

Therapeutic Effect of Gypenosides on Antioxidant Stress Injury in Orbital Fibroblasts of Graves' Orbitopathy
por: Ma, Chao, et al.
Publicado: (2022)

Rapamycin improves Graves’ orbitopathy by suppressing CD4(+) cytotoxic T lymphocytes
por: Zhang, Meng, et al.
Publicado: (2023)

Endoscopic intranasal orbital decompression in the course of Graves’ orbitopathy
por: Krzeski, Antoni, et al.
Publicado: (2013)

Association between Polymorphisms in the TSHR Gene and Graves' Orbitopathy
por: Jurecka-Lubieniecka, Beata, et al.
Publicado: (2014)

Not All Orbitopathy Is Graves’: Discussion of Cases and Review of Literature
por: Boddu, Neeraja, et al.
Publicado: (2017)

Teprotumumab: a disease modifying treatment for graves’ orbitopathy
por: Ting, Michelle, et al.
Publicado: (2020)

Factors associated with severity of orbitopathy in patients with Graves' disease
por: Nabi, Tauseef, et al.
Publicado: (2020)

Challenges and perspectives of selenium supplementation in Graves’ disease and orbitopathy
por: Bednarczuk, Tomasz, et al.
Publicado: (2019)

Glucocorticoids in Graves’ orbitopathy: mechanisms of action and clinical application
por: Längericht, Jan, et al.
Publicado: (2020)

Adipocytokines in Graves’ orbitopathy and the effect of high-dose corticosteroids
por: Schovanek, Jan, et al.
Publicado: (2021)

IgG4 as a Biomarker in Graves' Orbitopathy
por: Olejarz, Michał, et al.
Publicado: (2021)

Acute Corneal Hydrops in Keratoconus Patients with Graves’ Orbitopathy
por: Dogan, Aysun Sanal, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2c1bnv9nide5s0rpcs77sv6be0